Yuan Ji, BS, MS, PhD, FACMG

Languages

  • Chinese
  • English

Academic Information

  • Departments: Pathology - Assistant Professor (Clinical)
  • Divisions: Clinical Pathology

Academic Office Information

  • 801-583-2787-Ext-3251
  • ARUP Laboratories
    500 S Chipeta Way
    Salt Lake City, UT 84108

Email: yuan.ji@path.utah.edu

Education History

Type School Degree
Fellowship Mayo Clinic
ABMGG-Clinical Molecular Genetics
Fellow
Post Graduate Training Mayo Clinic
Clinical and Translational Science Postdoctoral Fellowship Certificate Program
Certificate
Certification John Hopkins - Jackson Laboratory
Short Course on Medical and Experimental Mammalian Genetics
Certificate
Fellowship Mayo Clinic
NIH-T32 Clinical Pharmacology
Fellow
Research Fellow Mayo Clinic
Pharmacogenomics
Postdoctoral Research Fellow
Doctoral Training Mayo Clinic
Pharmacology
Ph.D.
Graduate Training Xiamen University
Oncology
M.S.
Undergraduate Xiamen University
Biotechnology
B.S.

Global Impact

Education History

Type School Degree Country
Graduate Training Xiamen University
Oncology
M.S. China
Undergraduate Xiamen University
Biotechnology
B.S. China

Selected Publications

Journal Article

  1. Shen W, Young BA, Bosworth M, Wright KE, Lamb AN, Ji Y (02/05/2018). Prenatal detection of uniparental disomy of chromosome 2 carrying a CHRND pathogenic variant that causes lethal multiple pterygium syndrome. Clin Genet.
  2. Wu JH, Tian W, Tian GL, Sumner K, Hutchinson D, Ji Y (01/01/2018). A systematic investigation of PIK3CA mutations in isolated macrodactyly: indication for accurate classification, diagnosis, and novel therapeutics. J Hand Surg Eur Vol.
  3. Pratt VM, Tredici ALD, Hachad H, Ji Y, Kalman L, Scott SA, Weck KE (02/21/2018). CYP2C19 Genotyping Recommendations: A Report of the Association for Molecular Pathology. J Mol Diagn, 20(3), 269-276.
  4. Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, Bruflat JK, Peterson LM, Veldhuizen TL, Fadra N, Peterson SE, Lagerstedt SA, Train LJ, Baudhuin LM, Klee EW, Ferber MJ, Bielinski SJ, Caraballo PJ, Weinshilboum RM, Black JL 3rd (2016). Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. J Mol Diagn, 18(3), 438-45.
  5. Hicks JK, Bishop JR, Sangkuhl K, Mller DJ, Ji Y, Leckband SG, Leeder JS, Chiulli DL, Graham RL, LLerena A, Skaar TC, Klein TE, Caudle KE, Gaedigk A (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther, 98(2), 127-34.
  6. Lindor NM, Schahl KA, Johnson KJ, Hunt KS, Mensink KA, Wieben ED, Klee E, Black JL, Highsmith WE Jr, Thibodeau SN, Ferber MJ, Aypar U, Ji Y, Graham RP, Fiksdal AS, Sarangi V, Ormond K, Riegert-Johnson DL, McAllister TM, Farrugia G, McCormick JB (2015). Whole Exome Sequencing of 10 Scientists: Evaluation of Process and Outcomes. Mayo Clin Proc, 90(10), 1327-37.
  7. Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmoller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Baune BT, Kato M, Liu YL, Praphanphoj V, Stingl JC, Tsai SJ, Kubo M, Klein TE, Weinshilboum R (2015). The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry, 5, e553.
  8. Ji Y, Schaid DJ, Desta Z, Kubo M, Batzler AJ, Snyder K, Mushiroda T, Kamatani N, Ogburn E, Hall-Flavin D, Flockhart D, Nakamura Y, Mrazek DA, Weinshilboum RM (2014). Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. British Journal of Clinical Pharmacology, 78(2), 373-83.
  9. Ellsworth KA, Moon I, Eckloff BW, Fridley BL, Jenkins GD, Batzler A, Biernacka JM, Abo R, Brisbin A, Ji Y, Hebbring S, Wieben ED, Mrazek DA, Weinshilboum RM, Wang L (2013). FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics, 23(3), 156-66.
  10. Ji Y, Biernacka JM, Hebbring S, Chai Y, Jenkins GD, Batzler A, Snyder KA, Drews MS, Desta Z, Flockhart D, Mushiroda T, Kubo M, Nakamura Y, Kamatani N, Schaid D, Weinshilboum RM, Mrazek DA (2013). Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J, 13(5), 456-63.
  11. Thorn CF, Ji Y, Weinshilboum RM, Altman RB, Klein TE (2012). PharmGKB summary: very important pharmacogene information for GSTT1. Pharmacogenet Genomics, 22(8), 646-51.
  12. Ji Y, Nordgren KK, Chai Y, Hebbring SJ, Jenkins GD, Abo RP, Peng Y, Pelleymounter LL, Moon I, Eckloff BW, Chai X, Zhang J, Fridley BL, Yee VC, Wieben ED, Weinshilboum RM (2012). Human liver methionine cycle: MAT1A and GNMT gene resequencing, functional genomics, and hepatic genotype-phenotype correlation. Drug Metab Dispos, 40(10), 1984-92.
  13. Hebbring SJ, Chai Y, Ji Y, Abo RP, Jenkins GD, Fridley B, Zhang J, Eckloff BW, Wieben ED, Weinshilboum RM (2012). Serine hydroxymethyltransferase 1 and 2: gene sequence variation and functional genomic characterization. J Neurochem, 120(6), 881-90.
  14. Ji Y, Biernacka J, Snyder K, Drews M, Pelleymounter LL, Colby C, Wang L, Mrazek DA, Weinshilboum RM (2012). Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. Pharmacogenomics J, 12(1), 78-85.
  15. Fridley BL, Jenkins GD, Batzler A, Wang L, Ji Y, Li F, Weinshilboum RM (2012). Multivariate models to detect genomic signatures for a class of drugs: application to thiopurines pharmacogenomics. Pharmacogenomics J, 12(2), 105-10.
  16. Abo R, Hebbring S, Ji Y, Zhu H, Zeng ZB, Batzler A, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Fridley B, Schaid D, Kamatani N, Nakamura Y, Kubo M, Mushiroda T, Kaddurah-Daouk R, Mrazek DA, Weinshilboum RM (2012). Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics, 22(4), 247-53.
  17. Feng Q, Kalari K, Fridley BL, Jenkins G, Ji Y, Abo R, Hebbring S, Zhang J, Nye MD, Leeder JS, Weinshilboum RM (2011). Betaine-homocysteine methyltransferase: human liver genotype-phenotype correlation. Mol Genet Metab, 102(2), 126-33.
  18. Fridley BL, Batzler A, Li L, Li F, Matimba A, Jenkins GD, Ji Y, Wang L, Weinshilboum RM (2011). Gene set analysis of purine and pyrimidine antimetabolites cancer therapies. Pharmacogenet Genomics, 21(11), 701-12.
  19. Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Zeng Z, Schaid D, Mrazek DA, Kaddurah-Daouk R, Weinshilboum RM (2011). Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther, 89(1), 97-104.
  20. Moyer AM, Fridley BL, Jenkins GD, Batzler AJ, Pelleymounter LL, Kalari KR, Ji Y, Chai Y, Nordgren KK, Weinshilboum RM (2011). Acetaminophen-NAPQI hepatotoxicity: a cell line model system genome-wide association study. Toxicol Sci, 120(1), 33-41.
  21. Li F, Fridley BL, Matimba A, Kalari KR, Pelleymounter L, Moon I, Ji Y, Jenkins GD, Batzler A, Wang L, Weinshilboum RM (2010). Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity. Drug Metab Dispos, 38(12), 2329-38.
  22. Zhang J, Ji Y, Moon I, Pelleymounter LL, Ezequel Salavaggione O, Wu Y, Jenkins GD, Batzler AJ, Schaid DJ, Weinshilboum RM (2009). Catechol O-methyltransferase pharmacogenomics: human liver genotype-phenotype correlation and proximal promoter studies. Pharmacogenet Genomics, 19(8), 577-87.
  23. Ji Y, Snyder EM, Fridley BL, Salavaggione OE, Moon I, Batzler A, Yee VC, Schaid DJ, Joyner MJ, Johnson BD, Weinshilboum RM (2008). Human phenylethanolamine N-methyltransferase genetic polymorphisms and exercise-induced epinephrine release. Physiol Genomics, 33(3), 323-32.
  24. Ji Y, Olson J, Zhang J, Hildebrandt M, Wang L, Ingle J, Fredericksen Z, Sellers T, Miller W, Dixon JM, Brauch H, Eichelbaum M, Justenhoven C, Hamann U, Ko Y, Bruning T, Chang-Claude J, Wang-Gohrke S, Schaid D, Weinshilboum R (2008). Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res, 68(14), 5997-6005.
  25. Ji Y, Moon I, Zlatkovic J, Salavaggione OE, Thomae BA, Eckloff BW, Wieben ED, Schaid DJ, Weinshilboum RM (2007). Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: gene sequence variation and functional genomics. J Pharmacol Exp Ther, 322(2), 529-40.
  26. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, Ames MM, Weinshilboum RM (2006). Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res, 12(6), 1794-803.
  27. Ji Y, Salavaggione OE, Wang L, Adjei AA, Eckloff B, Wieben ED, Weinshilboum RM (2005). Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics. J Neurochem, 95(6), 1766-76.
  28. Wu Q, Ji Y, Zhang MQ, Chen YQ, Chen F, Shi DL, Zheng ZH, Huang YJ, Su WJ (2003). Role of tumor metastasis suppressor gene KAI1 in digestive tract carcinomas and cancer cells. Cell Tissue Res, 314(2), 237-49.
  29. Ji Y, Qiao W (2002). New members of p53 family, p63 and p73. Chin J Cancer, 21, 1164-7.

Review

  1. Ji Y, Si C, co-first author, McMillin G, Lyon E (04/23/2018). Clinical pharmacogenetics testing in the era of next generation sequencing: challenges and opportunities for precision medicine. [Review]. Expert Review of Molecular Diagnostics.

Book Chapter

  1. Ji Y (Under revision). Pharmacogenomics: The use of pharmacogenomics in oncology. In Gregory J. Tsongalis, Ann Moyer (Eds.), Advances in Molecular Pathology (1.1). Philadelphia, PA: ELSEVIER.

Other

  1. Dai N, Foldager L, Gallego JA, Hack LM, Ji Y, Lett TA, Liu BC, Loken EK, Mandelli L, Mehta D, Power RA, Sprooten E, Stephens SH, Paska AV, Yan J, Zai CC, Zai G, Zhang-James Y, OShea A, Delisi LE (2012). Summaries from the XIX World Congress of Psychiatric Genetics, Washington, DC, September 10-14, 2011. Am J Med Genet B Neuropsychiatr Genet (159B(1), pp. 128-9). United States.

Poster

  1. Ji Y (2017). A cost-effective analysis of somatic mosaic PIK3CA mutations in PIK3CA-related segmental overgrowth disorders using targeted Sanger sequencing and a next-generation sequencing cancer hotspot panel. Poster session presented at Association for Molecular Pathology (AMP) 2017 Annual Meeting, Salt Lake City.
  2. Ji Y (2017). A systematic investigation of PIK3CA mutations in isolated macrodactyly: indication for accurate classification, diagnosis and potential novel therapeutics. Poster session presented at 72th Annual Meeting of the American Society for Surgery of the Hand (ASSH), San Francisco, CA.
  3. Ji Y (2017). Comparative Analysis of Clinical Whole Exome Sequencing (WES) with Targeted Genotyping Identified Areas for Improving Accuracy of WES-based Pharmacogenetic Profiling. Poster session presented at ACMG Annual Clinical Genetics Meeting, American College of Medical Genetics and Genomics (ACMG), Phoenix, AZ.
  4. Ji Y (2015). Preemptive pharmacogenomic testing: a comprehensive analysis of five actionable pharmacogenomic genes using next generation DNA sequencing and a customized CYP2D6 genotyping cascade. Poster session presented at AMP Annual Meeting, Association for Molecular Pathology (AMP), Austin, TX.
  5. Ji Y (2015). Targeted Next Generation Sequencing Frequently Changes Therapy Decisions for Advanced Colorectal Patients. Poster session presented at ACMG Annual Clinical Genetics Meeting, American College of Medical Genetics and Genomics (ACMG), Salt Lake City, UT.
  6. Ji Y (2014). Whole Exome Sequencing Reveals Novel Variant in CACNA1A Gene in a Patient with Global Developmental Delay. Poster session presented at ACMG Annual Clinical Genetics Meeting, American College of Medical Genetics and Genomics (ACMG), Nashville, TN.
  7. Ji Y (2013). H Liver Methylation Cycle: Mat1a And Gnmt Gene Resequencing, Functional Genomics And Hepatic Genotype-Phenotype Correlation. Poster session presented at 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), Indianapolis, IN.
  8. Ji Y (2012). Pharmacometabolomics-informed Pharmacogenomics. Poster session presented at 53rd Annual Short Course on Medical and Experimental Mammalian Genetics, The Jackson Laboratory, Bar Harbor, ME.
  9. Ji Y (2011). Glycine and a Glycine Dehydrogenase (GLDC) SNP as SSRI Response Biomarkers in Depression: Pharmacometabolomics-informed Pharmacogenomics. Poster session presented at 2011 Clinical and Translational Research and Education Meeting: ACRT/AFMR/SCTS Joint Annual Meeting, Washington, DC.
  10. Ji Y (2009). Breast Cancer Risk Reduction and Membrane-Bound Catechol O-Methyltransferase Genetic Polymorphisms. Poster session presented at Pharmacogenomics Research Network External Scientific Panel (PGRN-ESP) Scientific and Steering Committee Meeting, Vanderbilt University, Nashville, TN.
  11. Ji Y (2009). Catechol O-methyltransferase Pharmacogenomics and Selective Serotonin Reuptake Inhibitor Response in Major Depression. Poster session presented at 8th Annual Psychiatric Genomics: Applications for Clinical Practice, Mayo Clinic CME, Rochester, MN.
  12. Ji Y (2008). Membrane-bound (MB) Catechol O-methyltransferase (COMT) Genetic Polymorphisms, Catecholestrogen Conjugation and Breast Cancer Risk Reduction. Poster session presented at 109th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), Orland, FL.
  13. Ji Y (2007). Human Phenylethanolamine N-Methyltransferase Pharmacogenetics: Genotype-phenotype correlation analysis of exercise-activated epinephrine levels. Poster session presented at 108th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), Anaheim, CA.
  14. Ji Y (2005). Human Phenylethanolamine N-Methyltransferase (PNMT) Functional Genomics. Poster session presented at 13th North American ISSX Meeting, International Society for the Study of Xenobiotics (ISSX), Maui, HI.
  15. Ji Y (2004). Human phenylethanolamine N-methyltransferase (PNMT) pharmacogenetics: gene resequencing and functional genomic studies. Poster session presented at 105th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), Miami, FL.